C49.2 vs C79.89

C49.2 (Malignant neoplasm of connective and soft tissue of lower limb, including hip) compared with C79.89 (Secondary malignant neoplasm of other specified sites), from the official CMS tabular data. C49.2 and C79.89 name the same anatomical site (aponeurosis) with a different neoplasm behavior. MedCoder-derived

Relationship

Informational

Neoplasm table relationship

C49.2

Malignant neoplasm of connective and soft tissue of lower limb, including hip

↔

C79.89

Secondary malignant neoplasm of other specified sites

Same anatomical site, different neoplasm behavior.

Same site — secondary malignancy (aponeurosis)

The behavior documented for the site — malignant primary, secondary, carcinoma in situ, benign, uncertain or unspecified — decides which column of the neoplasm table, and therefore which code, applies.

Source: CMS Table of Neoplasms

Can these codes be reported together?

Same site, different neoplasm behavior. C49.2 and C79.89 name the same anatomical site (aponeurosis) with a different neoplasm behavior.

From the CMS/CDC Table of Neoplasms: the behavior documented for that site — malignant primary, secondary, carcinoma in situ, benign, uncertain or unspecified — decides which column, and therefore which code, applies.

Side by side

	C49.2Malignant neoplasm of connective and soft tissue of lower limb, including hip	C79.89Secondary malignant neoplasm of other specified sites
Billing status	Non-billable header Report instead: C49.20, C49.21, C49.22	Billable
Classification	C00-D49 — Neoplasms	C00-D49 — Neoplasms
Definition	Malignant neoplasm of connective and soft tissue of lower limb, including hip is a non-billable ICD-10-CM category code (C49.2).	Secondary malignant neoplasm of other specified sites is a billable ICD-10-CM diagnosis code (C79.89).
Includes	malignant neoplasm of blood vessel malignant neoplasm of bursa malignant neoplasm of cartilage malignant neoplasm of fascia	—

Edit this comparison Check a whole claim

Derived from the official CMS ICD-10-CM tabular data (FY2026). Not billing advice; verify sequencing rules for the encounter. All data sources